CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 44 enrolled
Drug / intervention
Vonoprazan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04729101
NCT04729101Phase 1Completed
CompareCT.gov

A Phase 1, Open-Label, Randomized, Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan (20 mg) and Lansoprazole (30 mg) in Healthy Subjects

Phathom Pharmaceuticals, Inc.·interventional·Posted Jan 28, 2021·Updated Mar 31, 2023

In Brief

A Phase 1 clinical trial evaluating Vonoprazan and Lansoprazole for Healthy Participants. Completed, enrolled 44 participants across 1 site.

Detailed Summary

To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of vonoprazan (20 mg) and lansoprazole (30 mg) following single (Day 1) and multiple doses (Day 7).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
202120222023202420252026
First PostedJan 28, 2021
Enrollment StartJan 28, 2021
Primary CompletionJun 12, 2021
Study CompletionJun 26, 2021
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 5.4 years ago

Interventions

Vonoprazandrug

Oral tablet

Lansoprazoledrug

Oral capsule